J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...

Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...

Revolutionary new software for the treatment of atrial fibrillation (AFib) has been rolled out for Irish patients in Dublin’s ...

Boston Scientific announced won CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software.

The tools ideate on Boston Scientific’s Farapulse PFA system, which contributed towards a 172% uptick in the company’s Q4 ...

The Parnassus Growth Equity Fund returned 4.85% (net) for Q4 2024, underperforming the Russell 1000 Growth Index’s 7.07%.

ALBANY, N.Y. ( NEWS10) — A new device is transforming the type of treatment some heart patients with atrial fibrillation receive. Doctors say it’s safer to use and improving outcomes for those who ...

We recently compiled a list of the 10 Best Momentum Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Most people aren’t aware of the symptoms, especially if they’re otherwise healthy, because they don’t know that AFib can affect anyone!

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

The company expects its 2025 adjusted earnings to be in the range of $2.80 to $2.87 per share, above analysts' average ...

Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...